US 11,655,283 B2
HLA-G transcripts and isoforms and their uses
Edgardo D. Carosella, Paris (FR); Diana Tronik-Le Roux, Meudon (FR); Jean-Philippe Deslys, La Celle Saint-Cloud (FR); Jérôme Verine, Antony (FR); François Desgrandchamps, Paris (FR); Nathalie Rouas-Freiss, Paris (FR); and Joël Le Maoult, Melun (FR)
Assigned to COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, Paris (FR); and ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris (FR)
Appl. No. 16/625,254
Filed by COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, Paris (FR); and ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris (FR)
PCT Filed Jul. 24, 2018, PCT No. PCT/EP2018/070061
§ 371(c)(1), (2) Date Dec. 20, 2019,
PCT Pub. No. WO2019/020641, PCT Pub. Date Jan. 31, 2019.
Claims priority of application No. 17305986 (EP), filed on Jul. 24, 2017.
Prior Publication US 2020/0148743 A1, May 14, 2020
Int. Cl. A61K 38/17 (2006.01); C07K 14/47 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C12N 15/79 (2006.01)
CPC C07K 14/70539 (2013.01) [A61K 38/1709 (2013.01); A61K 38/1774 (2013.01); C07K 14/47 (2013.01); C07K 16/2833 (2013.01); C12N 15/79 (2013.01); C07K 2317/33 (2013.01)] 2 Claims
 
1. A method of treating ischemia, comprising administering to a subject in need thereof a therapeutically effective amount of an isolated HLA-G protein, wherein the sequence of the isolated HLA-G protein is devoid of transmembrane/cytoplasmic domain and comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, and SEQ ID NO: 30.